Abiopharma

VERACYTE, INC. (VCYT)

Symbol	VCYT
Name	VERACYTE, INC.
Sector	HEALTH CARE
Region	North America
Industry	Medical Specialities
Address	6000 SHORELINE COURT,SUITE 300, SOUTH SAN FRANCISCO, California, 94080, United States
Telephone	+1 650 243-6300
Fax	—
Email	—
Website	https://www.veracyte.com
Incorporation	UNDEFINED
Incorporated On	—
Employees	—
Fiscal Year	—
Public Since	—
Exchanges	NASDAQ
Auditor	—
Audit Status	NOT PROVIDED
Reporting Status	—
CIK	0001384101
Description	Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firms product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others. The company derives its revenues from the Sale of Afirma analysis product. Additional info from NASDAQ: Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firms product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others. The company derives its revenues from the Sale of Afirma analysis product.

2026-07-30 20:18

(30% Negative) VERACYTE, INC. (VCYT) Reports Q3 2026 Financial Results

2026-07-28 20:05

Veracyte to Participate in Upcoming Investor Conferences

2026-06-15 20:56

Director EASTHAM KARIN 🟢 acquired 5.3K shares of VERACYTE, INC. (VCYT) Transaction Date: Jun 11, 2026 | Filing ID: 000004

2026-06-15 20:56

Director Shafer David Brent 🟢 acquired 5.3K shares of VERACYTE, INC. (VCYT) Transaction Date: Jun 11, 2026 | Filing ID: 000004

2026-06-15 20:56

Director Barr Eliav 🟢 acquired 5.3K shares of VERACYTE, INC. (VCYT) Transaction Date: Jun 11, 2026 | Filing ID: 000002

2026-06-15 20:55

Director EPSTEIN ROBERT S 🟢 acquired 5.3K shares of VERACYTE, INC. (VCYT) Transaction Date: Jun 11, 2026 | Filing ID: 000004

2026-06-15 20:55

Director Holstein Jens 🟢 acquired 5.3K shares of VERACYTE, INC. (VCYT) Transaction Date: Jun 11, 2026 | Filing ID: 000002

2026-06-15 20:55

Director Bhanji Muna 🟢 acquired 5.3K shares of VERACYTE, INC. (VCYT) Transaction Date: Jun 11, 2026 | Filing ID: 000002

2026-06-15 20:55

Director Miller Thomas F. 🟢 acquired 5.3K shares of VERACYTE, INC. (VCYT) Transaction Date: Jun 11, 2026 | Filing ID: 000002

2026-06-11 20:32

(99% Neutral) VERACYTE, INC. (VCYT) Announces New Board Appointment

Trial ID	Title	Phase	Indication	Status	Start Date	Completion Date	Source
NCT07282808	Focal or Radical Therapy: a Lesion-based Molecular Evaluation in Prostate Cancer	Na	Prostate Cancer	Recruiting	2026-01-01	2048-09-01	ClinicalTrials.gov
NCT06990542	Image-guided, Tumor-focused Radiotherapy Treatment in Intermediate and High-ris…	Phase2	Prostate Cancer	Recruiting	2025-06-09	2033-12-01	ClinicalTrials.gov
NCT06332274	tislelizUMaB in canceR Patients With molEcuLar residuaL Disease	Phase3	Cancer	Recruiting	2025-04-16	2030-04-01	ClinicalTrials.gov
NCT06282588	Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Mo…	Phase2	Prostate Cancer	Recruiting	2023-12-13	2030-12-31	ClinicalTrials.gov
NCT06426628	Clinical Utility of Management of Patients With Pulmonary Nodules Using the Per…	—	Pulmonary Nodule, Solitary	Recruiting	2022-07-18	2027-03-31	ClinicalTrials.gov
NCT03769415	Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel Ther…	Na	Breast Cancer	Recruiting	2018-11-06	2030-12-15	ClinicalTrials.gov
NCT02609269	Decipher Genomics Resource for Intelligent Discovery	—	Prostate Cancer	Enrolling_By_Invitation	2015-10-01	2040-12-01	ClinicalTrials.gov

Total clinical trials: 7

Product Name	Type	Development Stage	Therapeutic Area	Study Status	Trial ID
Decipher Cancer Classifier	Other	Preclinical	Prostate Cancer	ENROLLING_BY_INVITATION	NCT02609269
Decipher Cancer Classifier	Other	Preclinical	Prostate Cancer	ENROLLING_BY_INVITATION	NCT02609269
Placebo	Other	Phase PHASE3	Cancer	RECRUITING	NCT06332274
Blood sampling	Other	Phase PHASE3	Cancer	RECRUITING	NCT06332274
Tislelizumab	Other	Phase PHASE3	Cancer	RECRUITING	NCT06332274
Molecular Evaluation for Risk of Recurrence after FT	Other	Approved	Prostate Cancer	RECRUITING	NCT07282808
Intrinsic Subtyping of Primary Breast Cancer	Other	Approved	Breast Cancer	RECRUITING	NCT03769415
Image-guided tumor-focused radiation therapy	Drug	Phase PHASE2	Prostate Cancer	RECRUITING	NCT06990542
Docetaxel	Other	Phase PHASE2	Prostate Cancer	RECRUITING	NCT06282588
Firmagon 80 MG Injection	Other	Phase PHASE2	Prostate Cancer	RECRUITING	NCT06282588
Firmagon 120 MG Injection	Other	Phase PHASE2	Prostate Cancer	RECRUITING	NCT06282588
Depo-Eligard 7.5 mg	Other	Phase PHASE2	Prostate Cancer	RECRUITING	NCT06282588
Depo-Eligard 22.5 mg	Other	Phase PHASE2	Prostate Cancer	RECRUITING	NCT06282588
Depo-Eligard 45 mg	Other	Phase PHASE2	Prostate Cancer	RECRUITING	NCT06282588
Decapeptyl sustained release 11.25 mg	Other	Phase PHASE2	Prostate Cancer	RECRUITING	NCT06282588
Decapeptyl sustained release 22.5 mg	Other	Phase PHASE2	Prostate Cancer	RECRUITING	NCT06282588
Zoladex LA	Other	Phase PHASE2	Prostate Cancer	RECRUITING	NCT06282588
Zoladex 3.6Mg Implant	Other	Phase PHASE2	Prostate Cancer	RECRUITING	NCT06282588
Radiotherapy	Drug	Phase PHASE2	Prostate Cancer	RECRUITING	NCT06282588
Darolutamide matched placebo	Other	Phase PHASE2	Prostate Cancer	RECRUITING	NCT06282588
Darolutamide	Other	Phase PHASE2	Prostate Cancer	RECRUITING	NCT06282588
Image-guided tumor-focused radiation therapy	RADIATION	Phase PHASE2	Prostate Cancer	RECRUITING	NCT06990542
Placebo	DRUG	Phase PHASE3	Cancer	RECRUITING	NCT06332274
Blood sampling	OTHER	Phase PHASE3	Cancer	RECRUITING	NCT06332274
Tislelizumab	DRUG	Phase PHASE3	Cancer	RECRUITING	NCT06332274
Docetaxel	DRUG	Phase PHASE2	Prostate Cancer	RECRUITING	NCT06282588
Firmagon 80 MG Injection	DRUG	Phase PHASE2	Prostate Cancer	RECRUITING	NCT06282588
Firmagon 120 MG Injection	DRUG	Phase PHASE2	Prostate Cancer	RECRUITING	NCT06282588
Depo-Eligard 7.5 mg	DRUG	Phase PHASE2	Prostate Cancer	RECRUITING	NCT06282588
Depo-Eligard 22.5 mg	DRUG	Phase PHASE2	Prostate Cancer	RECRUITING	NCT06282588
Depo-Eligard 45 mg	DRUG	Phase PHASE2	Prostate Cancer	RECRUITING	NCT06282588
Decapeptyl sustained release 11.25 mg	DRUG	Phase PHASE2	Prostate Cancer	RECRUITING	NCT06282588
Decapeptyl sustained release 22.5 mg	DRUG	Phase PHASE2	Prostate Cancer	RECRUITING	NCT06282588
Zoladex LA	DRUG	Phase PHASE2	Prostate Cancer	RECRUITING	NCT06282588
Zoladex 3.6Mg Implant	DRUG	Phase PHASE2	Prostate Cancer	RECRUITING	NCT06282588
Radiotherapy	RADIATION	Phase PHASE2	Prostate Cancer	RECRUITING	NCT06282588
Darolutamide matched placebo	DRUG	Phase PHASE2	Prostate Cancer	RECRUITING	NCT06282588
Darolutamide	DRUG	Phase PHASE2	Prostate Cancer	RECRUITING	NCT06282588
Intrinsic Subtyping of Primary Breast Cancer	DEVICE	Approved	Breast Cancer	RECRUITING	NCT03769415
Decipher Cancer Classifier	OTHER	Preclinical	Prostate Cancer	ENROLLING_BY_INVITATION	NCT02609269

Total products: 40